Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro

Thrombosis Research

Volumn 113, Issue 5, 2004, Pages 333-339

  Tanaka, Kenichi A ^a   Szlam, Fania ^a   Katori, Nobuyuki ^a   Vega, J David ^b   Levy, Jerrold H ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY CLINIC   (United States)

Author keywords

Aprotinin; DX 88; Kallikrein inhibitor

Indexed keywords

APROTININ; HEPARIN; INFUSORIAL EARTH; KALLIKREIN INHIBITOR; KAOLIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; EVALUATION; HEMOSTASIS; HUMAN; IN VITRO STUDY; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME; VOLUNTEER;

APROTININ; DRUG EVALUATION, PRECLINICAL; HEMOSTASIS; HUMANS; KALLIKREINS; OLIGOPEPTIDES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; WHOLE BLOOD COAGULATION TIME;

EID: 2942618600     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.03.022     Document Type: Article

References (25)

1. Levy J.H., Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. 75:2003;S715-S720
2. Fujikawa K., Heimark R.L., Kurachi K., Davie E.W. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry. 19:1980;1322-1330
3. Mojcik C.F., Levy J.H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann. Thorac. Surg. 71:2001;745-754
4. Huang H., Ding W., Su Z., Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J. Thorac. Cardiovasc. Surg. 106:1993;11-18
5. Colman R.W., Edelman R., Scott C.F., Gilman R.H. Plasma kallikrein activation and inhibition during typhoid fever. J. Clin. Invest. 61:1978;287-296
6. DeLa Cadena R.A., Suffredini A.F., Page J.D., Pixley R.A., Kaufman N., Parrillo J.E., et al. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood. 81:1993;3313-3317
7. Markland W., Ley C.A., Ladner R.C. Iterative optimization of high affinity protease inhibitors using phage display: 2. Plasma kallikrein and thrombin. Biochemistry. 35:1996;8058-8067
8. Williams A., Baird L.G. DX-88 and HAE a developmental perspective. Transfus. Apher. Sci. 29:2003;255-258
9. Ritchie B.C. Protesase inhibitors in the treatment of hereditary angiedema. Transfus. Apher. Sci. 29:2003;256-259
10. Huyzen R.J., Harder M.P., Huet R.C., Boonstra P.W., Brenken U., van Oeveren W. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. J. Cardiothorac. Vasc. Anesth. 8:1994;153-156
11. Despotis G.J., Alsoufiev A., Goodnough L.T., Lappas D.G. Aprotinin prolongs whole blood activated partial thromboplastin time but not whole blood prothrombin time in patients undergoing cardiac surgery. Anesth. Analg. 81:1995;919-924
12. Avidan M.S., Da Fonseca J., Parmar K., Alcock E., Ponte J., Hunt B.J. The effects of aprotinin on thromboelastography with three different activators. Anesthesiology. 95:2001;1169-1174
13. Jensen N.F., Weiler J.M. C1 esterase inhibitor deficiency, airway compromise, and anesthesia. Anesth. Analg. 87:1998;480-488
14. Damas J., Adam A., Remacle-Volon G., Grek V. Studies on the vascular and hematological changes induced by ellagic acid in rats. Agents Actions. 22:1987;270-279
15. Gando S., Nanzaki S., Kemmotsu O. Coagulofibrinolytic changes after isolated head injury are not different from those in trauma patients without head injury. J. Trauma Inj. Infect. Crit. Care. 46:1999;1070-1076
16. Chandler W.L., Fitch J.C., Wall M.H., Verrier E.D., Cochran R.P., Soltow L.O., et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb. Haemost. 74:1995;1293-1297
17. Bonser R.S., Dave J., Morgan J., Morgan C., Davies E., Taylor P., et al. Complement activation during bypass in acquired C1 esterase inhibitor deficiency. Ann. Thorac. Surg. 52:1991;541-543
18. Wachtfogel Y.T., Kucich U., Hack C.E., Gluszko P., Niewiarowski S., Colman R.W., et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J. Thorac. Cardiovasc. Surg. 106:1993;1-9
19. Levy J.H., Pifarre R., Schaff H.V., Horrow J.C., Albus R., Spiess B., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244
20. Miller B.E., Tosone S.R., Tam V.K., Kanter K.R., Guzzetta N.A., Bailey J.M., et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann. Thorac. Surg. 66:1998;535-540
21. Casati V., Bellotti F., Gerli C., Franco A., Oppizzi M., Cossolini M., et al. Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesthesiology. 94:2001;8-14
22. Troianos C.A., Sypula R.W., Lucas D.M., D'Amico F., Mathie T.B., Desai M., et al. The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology. 91:1999;430-435
23. Dietrich W., Spath P., Zuhlsdorf M., Dalichau H., Kirchhoff P.G., Kuppe H., et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology. 95:2001;64-71
24. Alderman E.L., Levy J.H., Rich J., Nile M., Vidne B., Schaff H., et al. International multi-center aprotinin graft potency experience (IMAGE). J. Thorac. Cardiovasc. Surg. 116:1998;716-730
25. Mangano D.T. Multicenter Study of Perioperative Ischemia Research G Aspirin and mortality from coronary bypass surgery. [comment] N. Engl. J. Med. 347:2002;1309-1317